Bruker Corporation entered into an agreement to acquire ELITech Group SAS from Tecfin S.À R.L. for approximately ?870 million.

Bruker Corporation (NasdaqGS:BRKR) entered into an agreement to acquire ELITech Group SAS from Tecfin S.À R.L. for approximately ?870 million on February 27, 2024. Bruker expects to fund the acquisition using cash on hand and established debt financing. Upon closing, ELITech is expected to be a stand-alone business within Bruker?s Microbiology and Infection Diagnostics division, as a part of the Bruker CALID Group.

The transaction does not include the ELITech Group's ELITech clinical chemistry business, which will be carved out. The transaction is subject to regulatory approvals, the carve-out of the clinical chemistry business, and other customary closing conditions. Bruker expects to close the transaction in the second quarter of 2024.